Evidence map›Paper›PMID 38453518›Full record

ReviewBMJ global health2024

Collaboration within the global vaccine safety surveillance ecosystem during the COVID-19 pandemic: lessons learnt and key recommendations from the COVAX Vaccine Safety Working Group.

Rebecca E Chandler, Madhava Ram Balakrishnan, Daniel Brasseur, Philip Bryan, Emmanuelle Espie, Katharina Hartmann, Corinne Jouquelet-Royer, James Milligan, Linda Nesbitt, Shanthi Pal and 4 more

Abstract readReview
In one paragraph

Review in BMJ global health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Avidity maturation of anti-spike IgG after vaccination in COVID-19 convalescent vs COVID-19 naïve patients.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Rebecca E ChandlerCoalition for Epidemic Preparedness Innovations, Oslo, Norway rebecca.chandler@cepi.net.ORCID http://orcid.org/0000-0002-9334-9046
Madhava Ram BalakrishnanWHO, Geneva, Switzerland.
Daniel BrasseurIndependent Advisor, Brussels, Belgium.
Philip BryanP95 Epidemiology and Pharmacovigilance, Leuven, Belgium.
Emmanuelle EspieCoalition for Epidemic Preparedness Innovations, Oslo, Norway.
Katharina HartmannIndependent Advisor, Zurich, Switzerland.
Corinne Jouquelet-RoyerSanofi Pasteur, Lyon, France.
James MilliganCSL Seqirus, Maidenhead, UK.
Linda NesbittBiovac Institute, Pinelands, Cape Town, South Africa.
Shanthi PalWHO, Geneva, Switzerland.
Alexander PreciosoInstituto Butantan, São Paulo, Brazil.
Paulo TakeyBio-Manguinhos, Rio de Janeiro, Brazil.
Robert T ChenThe Task Force for Global Health, Decatur, Georgia, USA.
COVAX Vaccine Safety Working Group

Funding

World Health Organization 001
6 · The paper itself

Abstract

This analysis describes the successes, challenges and opportunities to improve global vaccine safety surveillance as observed by the Vaccine Safety Working Group from its role as a platform of exchange for stakeholders responsible for monitoring the safety of vaccines distributed through the COVAX mechanism. Three key elements considered to be essential for ongoing and future pandemic preparedness for vaccine developers in their interaction with other members of the vaccine safety ecosystem are (1) the availability of infrastructure and capacity for active vaccine safety surveillance in low-income and middle-income countries (LMICs), including the advancement of concepts of safety surveillance and risk management to vaccine developers and manufacturers from LMICs; (2) more comprehensive mechanisms to ensure timely exchange of vaccine safety data and/or knowledge gaps between public health authorities and vaccine developers and manufacturers; and (3) further implementation of the concept of regulatory reliance in pharmacovigilance. These aims would both conserve valuable resources and allow for more equitable access to vaccine safety information and for benefit/risk decision-making.

Indexed as

COVID-19VaccinesEcosystemHumansPandemicsPharmacovigilanceVaccinesCOVID-19Vaccines

Identifiers

PMID38453518
PMCPMC10921508

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.